Table 1.
Demographics and baseline variables
| ERAN | BSRBR | ||
|---|---|---|---|
| TNF inhibitor | Non-biologic | ||
| Total subjects | 828 | 9905 | 2581 |
| Age, years | 57 (14) | 56 (12) | 60 (12) |
| Female sex | 67% | 76% | 73% |
| BMI, kg/m2 | 27.6 (5.3) | 27.0 (7.3) | 27.4 (6.7) |
| Smoking status | |||
| Never | 39% | 40% | 38% |
| Ex-smoker | 25% | 38% | 41% |
| Current | 36% | 22% | 21% |
| Duration, years | 0.7 (0.6) | 13 (10) | 10 (10) |
| Positive serology | 60% | 65% | 57% |
| 1987 ACR criteria, yes | 53% | 100% | 100% |
| DAS28-ESR | 4.7 (1.5) | 6.6 (1.0) | 5.1 (1.3) |
| ESR, mm/h | 30 (24) | 46 (29) | 34 (24) |
| SJC, 0–28 | 6 (5) | 11 (6) | 6 (5) |
| TJC, 0–28 | 7 (7) | 16 (7) | 8 (7) |
| VAS, 0–100 | 44 (25) | 72 (20) | 54 (24) |
| HAQ, 0–3 | 1.1 (0.8) | 2.0 (0.6) | 1.5 (0.8) |
| SF-36 | |||
| Physical function | 30 (15) | 16 (11) | 24 (11) |
| Bodily pain | 33 (11) | 25 (7) | 31 (9) |
| Vitality | 42 (11) | 33 (10) | 39 (10) |
| Mental health | 46 (11) | 40 (11) | 45 (11) |
| PCS | 29 (12) | 16 (8) | 24 (11) |
| MCS | 47 (12) | 44 (11) | 48 (11) |
| DMARD by 6-month follow-up | 91% | 100% | 100% |
| First recorded DMARD | |||
| MTX monotherapy | 48% | 40% | 0% |
| SSZ monotherapy | 31% | 14% | 0% |
| MTX combination | 12% | 25% | 0% |
| Biologic | 0% | 0% | 100% |
Baseline variables of the complete cases for the cohorts. Mean (SD) or percentage data are presented
Abbreviations: ACR American College of Rheumatology, BSRBR British Society for Rheumatology Biologics Registers, DAS28 28-joint Disease Activity Score, DMARD Disease-modifying anti-rheumatic drug, ERAN Early Rheumatoid Arthritis Network, ESR Erythrocyte sedimentation rate, HAQ Health Assessment Questionnaire, SF-36 36-item Short Form Health Survey, SJC Swollen joint count, TJC Tender joint count, TNF Tumour necrosis factor, VAS Visual analogue scale, PCS Short Form Health Survey physical component score, MCS Short Form Health Survey mental component score, MTX methotrexate, SSZ sulphasalazine